Tumor growth rate (TGR) to monitor growth/predict response to lanreotide autogel use before, during and after PRRT in advanced GEP-NETS: data from the PRELUDE study
Authors
Bodei, LSrirajaskanthan, R
Grana, CM
Baldari, S
Shah, T
Lamarca, Angela
Courbon, F
Scheidhauer, K
Baudin, E
Roussy, G
Thanh, XMT
Houchard, A
Prasad, V
Affiliation
Memorial Sloan Kettering Cancer Center, New YorkIssue Date
2020